we could save lives

Every year more than 215.000 people die
of severe sepsis in the United States.


Adrenomed is currently developing a new drug to significantly decrease mortality in severe sepsis. Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise vascular integrity and cause tissue edema, organ dysfunction and death. Severe sepsis accounts for 20% of all admissions to intensive care units (ICUs) and is the leading cause of death in non-cardiac ICUs[1]. The incidence, outcome, and associated costs of care, clearly document an unmet medical need: in the USA, mortality from severe sepsis was 28.6%, or 215,000 deaths. Despite tremendous improvements in hospital hygiene and sepsis therapy strategies, the incidence of sepsis has doubled in the past 10 years and is still increasing[2].


Adrenomed’s mission is to provide life-saving therapies in sepsis.

New Publications

Recent scientific publications:

Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model

Joachim Struck, Frauke Hein, Siegmund Karasch, Andreas Bergmann

Intensive Care Medicine Experimental 2013, 1:3 (29 October 2013)

Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock

Katja Wagner, Ulrich Wachter, Josef A Vogt, Angelika Scheuerle, Oscar McCook, Sandra Weber, Michael Gröger, Bettina Stahl, Michael Georgieff, Peter Möller, Andreas Bergmann, Frauke Hein, Enrico Calzia, Peter Radermacher, Florian Wagner Intensive Care Medicine Experimental 2013, 1:2 (29 October 2013)

Adrenomedullin: it's double-edged sword during sepsis slices yet again

Kox M, Pickkers P.

Intensive Care Medicine Experimental 2014, 2:1

Endothelial Barrier Injury is directly related to Kidney Dysfunction in resuscitated murine shock model

Shock. 2015 Oct;44 Suppl 2:15-6